Two identical phase 3 RCTs (REMODEL-1 and REMODEL-2) compared oral remibrutinib 100 mg twice daily versus teriflunomide 14 mg once daily in adults aged 18–55 with relapsing MS and recent disease activity, over up to 30 months of follow-up (n=2,007 total).
Remibrutinib significantly reduced annualised relapse rate vs teriflunomide in both trials: ARR 0.073 vs 0.112 (rate ratio 0.648; p=0.018) in REMODEL-1 and 0.080 vs 0.116 (rate ratio 0.688; p=0.034) in REMODEL-2, representing roughly 31–35% relative reductions. Adverse events leading to discontinuation were less frequent with remibrutinib (3.1%) than teriflunomide (5.8%), and alopecia was notably less common (5.8% vs 13.5%).
Comparator was teriflunomide, a moderate-efficacy therapy, leaving remibrutinib's performance vs higher-efficacy agents unknown. Longer-term disability outcomes (e.g., confirmed disability progression) were not reported as primary endpoints. The trial population was capped at age 55 and required recent disease activity, limiting generalisability to older or lower-activity patients.
Remibrutinib, an oral CNS-penetrant BTK inhibitor, reduced relapse rates by about one-third compared to teriflunomide with a favourable tolerability profile, including fewer discontinuations and less alopecia. Clinicians treating relapsing MS may consider it a promising oral option, though head-to-head data against high-efficacy therapies are still needed.
Explore related topics